Results 131 to 140 of about 64,876 (258)

PAX8‐positive conventional urothelial carcinomas of the urinary bladder and their distinct molecular profiles – A clinicopathologic study of 101 consecutive cases with next‐generation sequencing in 20 cases

Histopathology, EarlyView.
PAX8 expression in urothelial carcinoma was investigated in 101 consecutive transurethral resections of the urinary bladder. PAX8 was positive in 10% of cases, with targeted molecular testing of these cases revealing universal TERT promoter mutations and frequent alterations in TSC1, NOTCH1 and WT1. Aims PAX8 immunohistochemistry (IHC) is often used to
Sarah Mae Lammert, Wendy Luo, Allen C Zhu, Peng Wang, Tatjana Antic, Jung Woo Kwon   +5 more
wiley   +1 more source

Harnessing blue light photobiomodulation for cancer therapy: Evidence from a systematic review

Photochemistry and Photobiology, EarlyView.
Conventional treatments for various types of cancer are often associated with tumor recurrence and aggressiveness. Photobiomodulation with blue light (BL; 450–470 nm) emerges as a promising alternative with antitumor effects. This systematic review, with 37 in vitro and in vivo studies from 2002 to 2024, revealed that BL reduces cell viability ...
Bárbara Evelyn Santos de Lima, Rebeca Barros Nascimento, Ana Paula Mariano Santos Ginez, Maria Stella Moreira, Rebeca Boltes Cecatto, Rodrigo Labat Marcos, Maria Fernanda Setúbal Destro Rodrigues   +6 more
wiley   +1 more source

Perinephric and Ovarian Metastasis from Advanced Urothelial Carcinoma Bladder: Case Report of a Rare Dismal Disease

Asian Pacific Journal of Cancer Care
Background: Metastatic urothelial carcinoma bladder at the time of diagnosis is a rare entity with lymph nodes, bones, lung and liver as common metastatic sites. Sometimes metastasis can be seen in various atypical sites.
Poorva Vias, Ashish Saklani, Suman Singh, Anantika Thakur, Era Sankhyan   +4 more
doaj   +1 more source

SUBDUE‐3: SUB‐urothelial DUrvalumab‐89zirconium injEction; a phase 0 biodistribution study protocol

BJU International, EarlyView.
Kevin G. Keane, Richard Gauci, Roslyn J. Francis, Andrew M. Scott, Cynthia Hawks, Andrisha‐Jade Inderjeeth, Ian D. Davis, Jayne Lim, Andrew Redfern, Dickon Hayne   +9 more
wiley   +1 more source

Laparoscopic stapled partial cystectomy with intraoperative cystourethroscopy for urothelial carcinoma in two dogs

Veterinary Surgery, EarlyView.
Abstract Objective To describe the procedure and short‐term outcomes of two dogs that underwent laparoscopic stapled partial cystectomy with intraoperative cystoscopy for excision of solitary, non‐trigonal, urothelial carcinoma lesions. Animals A 12‐year‐old female spayed mixed breed and a 13‐year‐old female spayed Siberian Husky.
Maureen A. Griffin, Christian Folk, Nicole J. Buote   +2 more
wiley   +1 more source

Deep early tumour shrinkage in metastatic upper tract urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab

BJU International, EarlyView.
Marie Semmler, Maurice Heimer, Can Aydogdu, Benazir Enzinger, Isabel Brinkmann, Frederik Kolligs, Gerald B. Schulz, Christian G. Stief, Philipp M. Kazmierczak, Jozefina Casuscelli, Lennert Eismann   +10 more
wiley   +1 more source

On why cancer cells require a great amount of glucose

Quantitative Biology, Volume 14, Issue 2, June 2026.
Abstract The traditional thinking has been that cancer cells require a great amount of glucose to support their rapid growth, but the reality may be different. We have previously demonstrated that all cancer cells in The Cancer Genome Atlas harbor persistent Fenton reactions in their cytosol, which generate OH− ${\text{OH}}^{-}$ and ultimately kill the
Xuechen Mu, Aoran Liu, Rui Shi, Long Xu, Zhenyu Huang, Ye Zhang, Ying Xu   +6 more
wiley   +1 more source

Early tumor response to intraarterial or intravenous administration of carboplatin to treat naturally occurring lower urinary tract carcinoma in dogs. [PDF]

, 2015
BackgroundSurvival times and tumor responses associated with malignant neoplasia of the lower urinary tract are poor despite the vast array of current treatments.
Berent, AC, Clifford, CA, Culp, WTN, Jackson, DE, Kass, PH, Krick, EL, Reetz, JA, Sorenmo, KU, Weisse, C   +8 more
core  

Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis

International Journal of Cancer, Volume 158, Issue 6, Page 1654-1665, 15 March 2026.
What's new? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Dora Niedersuess‐Beke, Karl Mayrhofer, Johanna Krauter, Johannes Franke, Dominic Vais, Maximillian Pallauf, David Kiesl, Ferdinand Luger, Jacob Pfuner, Angelika Terbuch, Thomas Bauernhofer, Jasmin Spielgelberg, Andreas Banner, Stefan Aufderklamm, Clemens Wiesinger, Susanne Schnabel, Simon Peter Gampenrieder, Josef Mühlmann, Sonia Vallet, Sabine Weibrecht, Franz Stoiber, Haleh Andalibi, Harun Fajkovic, Hossein Taghizadeh, Jan Miechowiecki, Roman Taedcke, Daniel Heintel, Shahrokh F. Shariat, Martin Pichler, Wolfgang Hilbe, Renate Pichler   +30 more
wiley   +1 more source

First reported case of peri-ureteric urothelial carcinoma

Urology Case Reports
We report the first documented case of peri-ureteric, low-grade urothelial carcinoma presenting over two decades after initial non–muscle-invasive bladder cancer (NMIBC). A 75-year-old male, treated with intravesical BCG, remained recurrence-free for ten
Mandana Gholami, Jimmy Lam
doaj   +1 more source